Therapeutic Misperceptions in Early-Phase Cancer Trials: From Categorical to Continuous

2018 ◽  
Vol 40 (4) ◽  
pp. 13-20 ◽  
Author(s):  
Bryan A. Sisk ◽  
Eric Kodish
Keyword(s):  
Early Phase ◽  
Cancer Trials

scholarly journals Purpose and Benefits of Early Phase Cancer Trials: What Do Oncologists Say? What Do Patients Hear?

2008 ◽  
Vol 3 (3) ◽  
pp. 57-68 ◽  
Author(s):  
Nancy Kass ◽  
Holly Taylor ◽  
Linda Fogarty ◽  
Jeremy Sugarman ◽  
Steven N. Goodman ◽  
...  
Keyword(s):  
Early Phase ◽  
Cancer Trials

scholarly journals The Impact of Patient Socio-Econonomic Status on Access to Early Phase Cancer Trials

2012 ◽  
Vol 23 ◽  
pp. ix165
Author(s):  
A. Mohd Noor ◽  
S. Vizor ◽  
B. McLennan ◽  
D. Sarker ◽  
H. Moller ◽  
...  
Keyword(s):  
Early Phase ◽  
Cancer Trials ◽  
The Impact

Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials

2013 ◽  
Vol 31 (2) ◽  
pp. 224-230 ◽  
Author(s):  
Aisyah Mohd Noor ◽  
Debashis Sarker ◽  
Suzanne Vizor ◽  
Blair McLennan ◽  
Sarah Hunter ◽  
...  
Keyword(s):  
Socioeconomic Status ◽  
Early Phase ◽  
Cancer Type ◽  
Cancer Trial ◽  
Nonwhite Population ◽  
Incident Cancer ◽  
Cancer Trials ◽  
Incident Cases ◽  
First Time ◽  
Index Of Multiple Deprivation

Purpose Little is known about the influence of socioeconomic factors on patient access to cancer trials. Differences should be considered to ensure generalizability of trial results and equality of access. Methods Phase I trials unit referrals at our center over 5 years, from 2007 to 2012, were reviewed. Socioeconomic status was defined by the Index of Multiple Deprivation (IMD; 1, least deprived; 5, most deprived). Multivariate analysis was performed comparing incident cancer cases with referred patients and those ultimately enrolled onto a trial. Results Four hundred thirty patients were referred (median age, 62 years). Compared with 10,784 incident cases, referral was less likely for patients in the more-deprived quintiles compared with the least deprived (IMD 5: odds ratio [OR], 0.53; 95% CI, 0.38 to 0.74). Once reviewed in the unit, enrollment onto a trial was not affected (IMD 5: OR, 0.81; 95% CI, 0.40 to 1.63). Ethnicity analysis showed the nonwhite population was less likely to be recruited (OR, 0.48; 95% CI, 0.26 to 0.88). This relationship was lost with adjustment for age, sex, cancer type, and deprivation index. Conclusion We show for the first time to our knowledge that socioeconomic status affects early-phase cancer trial referrals. The least-deprived patients are almost twice as likely to be referred compared with the most deprived. This may be because more-deprived patients are less suitable for a trial—as a result of comorbidities, for example—or because of inequalities that could be addressed by patient or referrer education. Once reviewed at the unit, enrollment onto a trial is not affected by deprivation.

Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials

Cancer ◽  
2013 ◽  
Vol 120 (2) ◽  
pp. 262-270 ◽  
Author(s):  
Chara Stavraka ◽  
David J. Pinato ◽  
Samantha J. Turnbull ◽  
Michael J. Flynn ◽  
Martin D. Forster ◽  
...  
Keyword(s):  
Patient Selection ◽  
Early Phase ◽  
Survival Benefit ◽  
Cancer Trials ◽  
Objective Marker

The effect of comorbidity on participation in early phase cancer trials.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2534-2534
Author(s):  
Ibrahim Sheriff ◽  
Henrik Møller ◽  
Jaya Ghosh ◽  
Aisyah Mohd Noor ◽  
Sophie Papa ◽  
...  
Keyword(s):  
Early Phase ◽  
Cancer Trials

Toxicity disparities between Hispanics and non-Hispanics enrolled in clinical trials in south Texas.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18089-e18089
Author(s):  
Ojas Harihar Vyas ◽  
Marcela Mazo- Canola ◽  
Juan Francisco Garza ◽  
Ruchi Hamal ◽  
Lashandra Royster ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Early Phase ◽  
Phase 1 ◽  
South Texas ◽  
Academic Center ◽  
History Of ◽  
Multiple Trials ◽  
Cancer Trials ◽  
Grade 3 ◽  
Early Phase Clinical Trials

e18089 Background: The U.S. Hispanic (H) population is estimated to increase from 55 million in 2014 to 119 million in 2060, growing from 17% to 29% of the total population. H are underrepresented in cancer trials. A review of practice-changing oncology trials showed only 3.9% of included patients were H. Disparities have been identified in time to diagnosis, treatment and outcomes in H patients, including those on clinical trials, despite uniform stage, treatment, and follow-up. Given our institution’s history of strong H accrual, we aimed to look at the rate of enrollment and toxicity in our early phase cancer trials of H compared with non-Hispanic whites (NHW). Methods: We retrospectively reviewed charts of patients enrolled in Phase I trials at UTHSCSA to assess rates of selected toxicities, death, hospitalizations and reasons for withdrawal from phase 1 trials. The following toxicities were recorded: anemia, neutropenia, neuropathy, nausea, vomiting, and fatigue. All H patients were compared to randomly selected statistical controls. Patients who were on multiple trials were excluded. Results: Of the 520 patients reviewed, 376 (72.3%) self-identified as H, 123(23.7%) as NHW, and 448 (86.2%) of patients had a solid tumor diagnosis. H and NHW with solid tumors are compared in the Table. They were similarly matched for sex, but H were noted to be older and more likely to receive cytotoxic therapy. Rates of patients experiencing any grade 3/4 toxicity or hospitalization were similar as shown. H were more likely to withdraw from trial due to disease progression. Conclusions: This retrospective analysis shows H patients did not experience significantly more toxicities in early phase clinical trials at an academic center in a minority-majority community. Prospective data collection is needed to provide more detailed information in the disparities that exist in toxicity and outcomes in H compared with NHW in cancer trials. [Table: see text]

scholarly journals Variations in Unrealistic Optimism Between Acceptors and Decliners of Early Phase Cancer Trials

2017 ◽  
Vol 12 (4) ◽  
pp. 280-288 ◽  
Author(s):  
Lynn A. Jansen ◽  
Daruka Mahadevan ◽  
Paul S. Appelbaum ◽  
William M. P. Klein ◽  
Neil D. Weinstein ◽  
...  
Keyword(s):  
Early Phase ◽  
Unrealistic Optimism ◽  
Cancer Trials

scholarly journals Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: a systematic review

2021 ◽  
pp. 102217
Author(s):  
Liza G.G. van Lent MA ◽  
Lea J. Jabbarian ◽  
Jelle van Gurp ◽  
Jeroen Hasselaar ◽  
Martijn P. Lolkema ◽  
...  
Keyword(s):  
Systematic Review ◽  
Early Phase ◽  
Clinical Cancer ◽  
Cancer Trials ◽  
Patient Values
Sign in / Sign up

Export Citation Format

Share Document